Program Book

exudative fluid from the hemangioma. Collapse of this structure may be
the origin of an epiretinal membrane.
Conclusions. Intraoperative PDT therapy is an option in pediatric VHL
patients with peripapillary hemangiomas. Technique for this procedure
performed under general anesthesia will be discussed.
Financial disclosure. None
105 OTp103
MEK INHIBITOR-ASSOCIATED SEROUS RETINOPATHY
- CLINICAL FEATURES OF A NEW RETINAL DISORDER
Scott C. N. Oliver, Raul Velez Montoya, Wells Messersmith, Jeffrey L
Olson, Naresh Mandava (scott.oliver@ucdenver.edu)
Departments of Ophthalmology and Medical Oncology, University of
Colorado School of Medicine, USA
Purpose. MAPK/ERK kinase (MEK) inhibitors are a promising class
of antineoplastic agents undergoing human clinical trial. This report
describes new findings of serous retinopathy and outer retinal thickening
not previously reported with these agents
Methods. Retrospective review
Results. Three patients with metastatic cancer had multiple central
scotomas 1,3, and 14 days after study drug initiation. Subneurosensory
fluid (SRF) was visible clinically and on optical coherence
tomography(OCT). Additionally, OCT identified diffuse outer retinal
thickening in areas not associated with fluid. FA and ICG angiography
did not show leakage. Findings resolved with drug discontinuation.
Conclusions. MEK inhibitor associated serous retinoapathy consists
of rapid onset localized SRF and diffuse outer retinal thickening. It
resembles, but is distinct from CSR, and requires further investigation.
Financial disclosure. Dr. Oliver is a consultant with Array Bioscience, Inc.
1450 OTp104
BENIGN TUMORS OF CILIARY BODY IN KOREAN
PATIENTS
Christopher Seungkyu Lee1A, Hee Jung Kwon1A, Hyae Min Jeon1B, Min
Kim1A, Sung Chul Lee1A (sklee219@yuhs.ac)
(A) Department of Ophthalmology,
(B) Department of Pathology,
(1) Yonsei University College of Medicine, Seoul, Korea
Purpose. To evaluate clinical features, management, histopathology,
and prognosis of benign ciliary body tumors in Korean patients.
Methods. A retrospective medical chart review was conducted on various
benign tumors of ciliary body that were evaluated by the authors between
2006 and 2011.
Results. All 8 patients underwent transscleral local resection of ciliary
body tumors, which were pathologically confirmed to be benign. Of 8, 3
were diagnosed with adenoma of nonpigmented ciliary body epithelium
(2 men, 1 woman; mean age 35 years; mean initial and final visual acuities
(VAs) 20/25 and 20/32 over 2 years), 1 was adenoma of pigmented ciliary
body epithelium (woman; 83 years; mean initial and final VAs 20/200
and light perception over 1 month), 2 were melanocytoma (2 men; mean
age 40 years; mean initial and final VAs 20/25 and 20/25 over 2 years),
1 was schwannoma (woman; 30 years; initial and final VAs 20/100 and
detecting hand movement over 5 years), and 1 was leiomyoma (woman;
46 years; initial and final VAs 20/400 and 20/80 over 1.5 years).
EYELID, CONJUNTIVA & ORBIT
Abstract Posters
87
Conclusions. Various benign tumors can be found in the ciliary body
that should be differentiated from malignant tumors, especially ciliary
body melanoma. Benign ciliary body tumors are rare and each type of
tumor has its characteristic clinical and histopathological features that
can suggest the diagnosis. In the management of these tumors, local
resection, rather than enucleation, should be considered first as the
treatment of choice. The visual prognosis was fair without any systemic
morbidity.
Financial disclosure. None
321 OTp105
TREATMENT OF SEROUS MACULAR DETACHMENT
ASSOCIATED WITH CIRCUMSCRIBED CHOROIDAL
HEMANGIOMA
Sung Chul Lee, Hee Jung Kwon, Min Kim, Christopher Seungkyu Lee
(sunglee@yuhs.ac)
Department of Ophthalmology, Institute of Vision Research, Yonsei
University College of Medicine, Seoul, Korea
Purpose. To evaluate the effect of transpupillary thermotherapy
(TTT) and intravitreal injection of bevacizumab (IVB) on serous
macular detachment (SMD) associated with circumscribed choroidal
hemangioma (CCH).
Methods. We retrospectively reviewed the records of CCH patients
treated by TTT and/or IVB to reduce SMD. We assessed changes in
visual acuity (VA), resolution of SMD and central fovea thickness (CFT) by
optical coherence tomography (OCT).
Results. Of 8 patients treated with TTT, 5 patients showed complete
resolution of SMD in OCT with improvement of median LogMAR VA from
0.7 to 0.22 (p=0.042). These 5 patients showed no recurrence of SMD
for a mean duration of 51.8 months, but SMD finally recurred in 4 of
them.
Of 9 patients treated with IVB, 5 patients showed resolution of SMD with
a decrease of median CFT from 514 µm to 330 µm (p=0.043). Of these 5
patients, 2 patients showed recurrence of SMD after 6.2 months.
In TTT group, 5 patients (3 patients in complete SMD resolution group,
2 patients in persistent SMD group) received additional IVB and 4 of
them also had cystoids macular edema (CME) with SMD before IVB.
All the patients showed persistent CME after IVB despite the complete
resolution of SMD in two of them.
Conclusions. In some patients with SMD in CCH, both TTT and IVB may
be used effectively. However, the duration of treatment effectiveness
appears to be longer in TTT than that in IVB. IVB for recurred SMD after
TTT Results in variable outcome but IVB had no effect on CME.
Financial disclosure. None
2132 OTp106
INTRAOCULAR RELAPSE OF MULTIPLE MYELOMA
RESPONSIVE TO BORTEZOMIB
Tero Kivelä (tero.kivela@helsinki.fi)
Department of Ophthalmology, Helsinki University Central Hospital,
Helsinki, Finland
Purpose. To report complete response to systemic bortezomib of a
relapse of multiple myeloma in the iris.
Methods. A 60-year-old man was diagnosed with multiple myeloma,